

Safety considerations in the use of glucagon-like peptide-1 receptor agonists

ESPERANZA MARTÍNEZ-ABUNDIS¹, MANUEL GONZÁLEZ-ORTIZ¹, ROSARIO ARECHAVELETA-GRANELL², RAFAEL M. VIOLANTE-ORTIZ², KARINA G. PÉREZ-RUBIO¹, ALEJANDRA M. RAMÍREZ-RODRÍGUEZ¹, MIRIAM MÉNDEZ-DEL VILLAR^{1*}

¹Institute of Experimental and Clinical Therapeutics, Physiology Department, Health Science University Center, University of Guadalajara; ²Clinical Investigation Area, Unidad de Patología Clínica. Guadalajara, Jal., Mexico;

³Internal Medicine Department, Regional General Hospital, Mexican Institute of Social Security, Tampico, Tamps., Mexico

ABSTRACT

A great variety of medications are currently available for the treatment of type 2 diabetes mellitus. Therefore, determining the efficacy and safety of these medications must be a priority for choosing the appropriate treatment for each patient. Glucagon-like peptide-1 receptor agonists are a relatively new and attractive option for type 2 diabetes mellitus treatment due to their capacity for reducing glycated hemoglobin A1c, weight loss, and low risk of hypoglycemia. Recently, some safety warnings have been published. Therefore, the purpose of this review is to objectively analyze the available information about the safety and tolerability of the different glucagon-like peptide-1 receptor agonists. (REV MEX ENDOCRINOL METAB NUTR. 2016;3:82-91)

Corresponding author: Miriam Méndez-del Villar, miriamendez@hotmail.com

Key words: Glucagon-like peptide-1 receptor agonist. Adverse event. Safety. Tolerability.

RESUMEN

Hoy en día existe una gran variedad de medicamentos disponibles para el tratamiento de la diabetes *mellitus* de tipo 2 (DM2), por lo que conocer su eficacia y seguridad debería ser prioritario para la elección del tratamiento adecuado para cada paciente. Los agonistas del receptor del péptido parecido al glucagón tipo 1 (aRGLP-1) son una opción atractiva y relativamente nueva para el tratamiento de la DM2 debido a su capacidad para reducir la hemoglobina glicada A1c, conseguir pérdida de peso y el bajo riesgo para producir hipoglucemia. Recientemente han sido publicadas algunas advertencias sobre la seguridad de su uso, por lo que el propósito de esta revisión es analizar de manera objetiva la información disponible sobre la seguridad y tolerabilidad de los diferentes aRGLP-1.

Palabras clave: Glucagón tipo 1 (aRGLP-1). Agonistas del receptor. Eventos adversos. Seguridad. Tolerabilidad

Correspondence to:

*Miriam Méndez-del Villar

J. Antonio Torres, 761

Col. Arcos de Guadalupe

C.P. 45037, Zapopan, Jal., México

E-mail: miriamendez@hotmail.com

Received for publication: 21-04-2016

Accepted for publication: 12-05-2016

INTRODUCTION

Choosing the best therapy for patients with type 2 diabetes mellitus (T2DM) is complicated. The choice must be based on its capacity to reduce glycated hemoglobin A1c (HbA1c), patient preferences, adverse events, risk of hypoglycemia, weight increase, and cost¹.

In regard to the algorithm of the American Diabetes Association and the European Association for the Study of Diabetes published in 2012², it is suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be used as an adjunct dual or triple therapy with metformin or other agents. The American Association of Clinical Endocrinologists in 2013³ proposed a treatment algorithm where GLP-1 RAs were highly ranked in the hierarchy of usage, even as monotherapy when metformin is contraindicated or not tolerated. The main reason for recommending GLP-1 RAs over other medications is due to their capacity to produce weight loss and their low hypoglycemic risk, along with some cardiovascular protection⁴⁻⁶.

Glucagon-like peptide-1 (GLP-1) receptors are expressed in different tissues such as pancreas, intestine, kidney, lung, thyroid, and brain, which could mediate some non-glucose effects, but this wide distribution may also produce different adverse effects⁷. In this review, safety would refer to the potential medical risk posed by a drug, and tolerability pertains to adverse effects as they affect patient acceptability of therapy⁸.

The aim of this review is provide in-depth information to the medical community regarding the safety and tolerability of GLP-1 RAs, along with offering physicians the capacity to explain all the benefits and risks of prescribing this kind of therapy.

SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS

Hypoglycemia

Hypoglycemia is the most important limiting factor in the pharmacologic treatment of T2DM; therefore,

diabetes treatment agents that minimize hypoglycemia have aroused great interest⁹.

Native GLP-1 stimulates insulin secretion in the presence of hyperglycemia and does not interfere with the counter-regulatory glucagon response to hypoglycemia¹⁰. The GLP-1 RAs have demonstrated similar glucose-dependent effects, which explains the relatively low risk of hypoglycemia with their use¹¹. The incidence of hypoglycemia depends mainly on the GLP-1 RAs and on the underlying therapy¹⁰.

A relative risk of mild hypoglycemia is demonstrated when GLP-1 RAs are used as monotherapy compared with placebo⁸. A 24-week monotherapy study of exenatide (5-10 µg twice daily) in treatment-naïve patients with type 2 diabetes yielded a 4-5% incidence of mild hypoglycemia compared with 1% for placebo, without major hypoglycemic episodes¹². Another study was carried out where liraglutide 1.8 mg vs. exenatide 10 µg was compared and demonstrated significantly fewer episodes of mild hypoglycemia with liraglutide compared with those using exenatide (1.9 vs. 2.6 events/patient-year; rate ratio 0.55; 95% CI: 0.34-0.88; $p = 0.0131$)¹³.

The combination of GLP-1 RAs and metformin has not been associated with an increase in the rate or severity of hypoglycemic events¹⁴⁻¹⁶. The combinations most often associated with hypoglycemia are GLP-1 RAs with sulfonylureas or with insulin^{17,18}.

The glucose-dependent insulinotropic action of GLP-1 RAs could be an effective option for patients who experience inadequate glycemic control with oral anti-diabetic agents and who need to intensify treatment with a relatively low risk of hypoglycemia. It is necessary to evaluate the underlying therapy of patients, for example, the use of sulfonylureas or insulin analogues, to consider a reduction of the concomitant therapy dose.

Use in kidney and liver disease

Preclinical studies indicated that exenatide is cleared via glomerular filtration and is the reason for the poor tolerance in patients with advanced renal disease¹⁹. The Food and Drug Administration (FDA)

recently requested a post-marketing report of renal impairment in association with the drug. Between April 2005 and October 2008 the agency received 78 reports of altered renal function in patients taking exenatide, sixty-two cases represented acute renal failure and 16 cases of renal insufficiency. Due to the above information, exenatide is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 ml/min) or end-stage renal disease (need for dialysis)²⁰.

Liraglutide is degraded by proteolysis; therefore, renal impairment or hepatic insufficiency has little effect on liraglutide pharmacokinetics^{21,22}. The European Union prescribing information points that no dose adjustment is required for patients with mild or moderate renal impairment (creatinine clearance 60-90 and 30-59 ml/min, respectively). There is little therapeutic experience in patients with severe renal impairment (creatinine clearance < 30 ml/min). For this reason, liraglutide cannot currently be recommended for use in patients with severe renal impairment, including patients with end-stage renal disease^{23,24}. Unlike the U.S. recommendations in regard to exenatide, labeling of liraglutide only indicates caution in regard to its use in patients with renal or hepatic impairment²³.

No current data are available in regard to renal damage with the use of lixisenatide. However, it is known that its clearance is predominantly through glomerular filtration with subsequent proteolytic degradation. For this reason, patients must be followed closely as with exenatide²⁵.

Despite the cases reported of acute renal failure in patients with T2DM treated with GLP-1 RAs, recent studies have associated GLP-1 RAs with renoprotective properties. In animal models, administration of GLP-1 RAs reduced systemic hypertension and albuminuria and therefore ameliorated renal damage. These data were histologically verified²⁶⁻²⁸.

Allergy, antibody formation, and injection-site reactions

The GLP-1 RAs are therapeutic peptides. Therefore, there is concern with regard to the development of

antidrug antibodies²⁹. Induction of an immune response is a well-known effect of protein-based drugs, which occurs less frequently with agents with more similarity to endogenous human proteins³⁰. Exenatide is derived from a non-mammalian source and has a homology of 53% with human GLP-1³¹, whereas liraglutide is based on the structure of human GLP-1, sharing a 97% amino acid sequence homology to the native protein³². This difference in homology with human GLP-1 could explain the lower incidence of antibody formation with liraglutide compared with exenatide.

Large clinical trials reported that 27-49% of patients treated with twice-daily exenatide developed drug antibodies^{12,33}. The rate of antibody formation is higher with once-weekly exenatide, occurring in 74% of patients³³. Antibodies to liraglutide, the GLP-1 RA with the highest homology with human GLP-1, were detected in only 4-13% of patients³⁴⁻³⁵. The greatest concern in regard to developing antidrug antibodies is that this could lead to a decreased efficacy of the medication or to an increase in hypersensitivity reactions over time³⁵.

Exenatide administered once weekly commonly causes a small lump at the injection site shortly after injection due to its microsphere formulation, which disappears within 3-4 weeks³⁶. Severe anaphylactic reactions with GLP-1 RAs have not been reported in clinical trials; however, post-marketing reports show that anaphylactic reactions rarely occur with liraglutide ($\geq 1/10,000$ to < $1/1,000$), very rarely with exenatide (< $1/10,000$) and uncommonly with lixisenatide ($\geq 1/1,000$ to < $1/1,000$)³⁷⁻⁴⁰.

Injection-site reactions, such as rash, erythema, or itching, are common with GLP-1 RAs. In phase II and III trials, 5.1% of patients receiving exenatide twice daily, 16% of patients receiving exenatide once weekly, and 3.9% of patients receiving lixisenatide experienced injection-site reactions, which are transient and generally do not cause treatment discontinuation³⁷⁻⁴⁰.

Musculoskeletal disorders

A meta-analysis of 16 randomized controlled trials (n = 11,206) assessed the risk of bone fractures

associated with GLP-1 RAs in comparison with placebo or other active drugs. Liraglutide was associated with a significantly decreased risk of incident bone fractures (OR: 0.38; 95% CI: 0.17-0.87), whereas exenatide was linked with an increased risk (OR: 2.09; 95% CI: 1.03-4.21)⁴¹.

Despite the negative effects reported in the meta-analysis with exenatide, a clinical trial that included 69 metformin-treated subjects with T2DM randomized to exenatide twice daily or insulin glargine showed no significant changes in serum alkaline phosphatase and calcium and phosphate levels. Bone mineral density was also similar in both groups after 44 weeks of therapy^{42,43}.

Infection

The GLP-1 RAs have been related with the presence of infections such as nasopharyngitis, influenza, cystitis, and viral infections, but no cause-effect association has been established³⁷⁻⁴⁰.

Cardiovascular system

In 2008 the FDA recommended that all drugs investigated for T2DM treatment should be evaluated to provide greater patient safety⁴⁴. A meta-analysis of 33 clinical trials with exenatide twice daily, exenatide weekly, liraglutide, taspoglutide and albiglutide showed no increase in major cardiovascular events and all-cause mortality when compared with placebo or other medications⁴⁵.

In some clinical trials a small but persistent increase in heart rate (2-4 beats/min) has consistently been observed in patients treated with GLP-1 RAs⁴⁶⁻⁴⁸. This increase in heart rate appears to be due to the activation of the GLP-1 receptors expressed by sinoatrial node myocytes⁴⁹, but it is unknown if this has any clinical significance on cardiovascular outcomes.

However, these agents have not been on the market for a long period of time and there is a lack of long-term safety data on cardiovascular mortality and other long-term cardiovascular parameters⁵⁰. Some

of the studies being carried out to evaluate GLP-1 RA cardiovascular outcomes are EXSCEL (exenatide once weekly), LEADER (liraglutide), REWIND (dulaglutide), and HARMONY (albiglutide)⁵¹⁻⁵⁴. One of the already concluded studies of cardiovascular outcomes is ELIXA, which was carried out with lixisenatide in patients with a recent acute coronary syndrome. Investigators concluded that in patients with T2DM and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events such as the presence of pancreatitis⁵⁵. The LEADER study of cardiovascular outcomes with liraglutide is already complete; however, results are still unknown²⁴.

Pancreatitis

A retrospective epidemiological study from the USA showed a threefold increase in pancreatitis in patients with T2DM compared with the general population⁵⁶. Known pancreatitis risk factors, such as obesity, biliary disease, hypertriglyceridemia, and use of sulfonylureas, are more common in patients with T2DM than in the general population^{57,58}.

Since U.S. approval of the use of exenatide from April 2005 until December 31, 2006, the FDA received 30 reports of acute pancreatitis in association with exenatide use, prompting the agency to request a new warning on the product label⁵⁹. The FDA also received six reports of cases of hemorrhagic or necrotizing pancreatitis in patients taking exenatide in recent years. Analysis of the 30 individual pancreatitis cases reported to the FDA of patients treated with exenatide showed that 90% involved known contributory factors such as obesity, gallstones, alcohol use, and hypertriglyceridemia, making it difficult to determine the actual cause of the pancreatitis⁶⁰.

According to a meta-analysis realized with diverse clinical trials and cohorts where adverse events were reported to the Adverse Event Reporting System (AERS) database⁶¹, which supports the FDA post-marketing pharmacovigilance, frequency of pancreatitis has been reported > 6-fold as an adverse event for patients administered exenatide

compared with other therapies for diabetes. Despite the fact that the AERS database can provide valuable information, it exhibits numerous and substantial limitations⁶². For this reason, further long-term pharmaco-epidemiological studies and clinical trials are necessary to prove if an association exists between pancreatitis and GLP-1 RAs.

Preclinical data show that GLP-1 receptors are expressed in exocrine pancreas cells, which have a proliferative capacity. This could result in an overgrowth, leading to partial obstruction, increased back pressure, and low-grade inflammation, which may result in the development of acute pancreatitis⁶³.

A study carried out to evaluate GLP-1 receptor activation by exenatide or liraglutide and the expression of some genes in the exocrine murine pancreas demonstrated that GLP-1 RAs do not predispose or exacerbate experimental pancreatitis in mice⁶⁴. In studies carried out in mice, rats, and monkeys exposed to liraglutide for two years at levels up to 60-times higher than in humans, it was also concluded that liraglutide treatment did not induce pancreatitis in those animals⁶⁵.

A recent systematic review that included 60 studies was carried out to analyze the risk of pancreatitis associated with incretin treatment in subjects with T2DM. The analysis of the randomized trials did not suggest an increased risk of pancreatitis with incretins vs. control (OR 1.1; 95% CI: 0.57-2.17). Estimates by type of incretin suggested similar results (OR 1.05; 95% CI: 0.37-2.94) for GLP-1 RAs vs. control. A non-observational study analysis suggested an increased risk of pancreatitis associated with incretin therapy⁶¹.

Because of the contradictory data regarding the relationship between GLP-1 RAs and risk of acute pancreatitis due to the presence of other contributing factors usually present in patients with T2DM, the FDA is continuously evaluating data for a better understanding of this safety issue and also urges both patients and healthcare professionals to report adverse events^{59,60}.

As cited above, the ELIXA study had the objective of rating cardiovascular events or other serious adverse events after the administration of lixisenatide during ~ 25 months to 6,068 patients with T2DM.

Investigators found that lixisenatide was not associated with a higher rate of serious adverse events or severe hypoglycemia, pancreatitis, pancreatic neoplasms, or allergic reactions when compared with placebo⁵⁴.

New studies being carried out with other GLP-1 RAs will probably show similar results. Both the FDA and the European Medicines Agency will potentially establish less stringent warnings about the use of GLP-1 RAs and the relation with the development of pancreatitis. The most recent documented data have not provided compelling evidence for increased risk of pancreatitis or pancreatic cancer⁶⁶.

Cancer

Glucagon-like peptide-1 seems to have much wider effects on the function and survival of cells that express its receptor. *In vivo* studies have demonstrated that insulin-gene transcription is stimulated, whereas cell apoptosis is inhibited by GLP-1 receptor activation and even stimulates cell growth, raising the issue of whether activation of the GLP-1 receptor pathway might have positive (i.e. restoration of the functional b-cell mass) or negative (i.e. inducing proliferation of premalignant lesions) effects when chronically used for the treatment of T2DM⁶⁷⁻⁶⁹.

An important aspect when analyzing whether specific antidiabetic agents, such as metformin, insulin, and GLP-1 RAs, increase the development of neoplasms is that considerable epidemiological evidence supports that T2DM itself represents a high risk for the development of certain types of cancer^{70,71}.

The main tissues where concerns are indicated in regard to the trophic effects of GLP-1 and its potential carcinogenic properties are pancreas and thyroid. Recent studies, however, also demonstrated that GLP-1 RAs could have beneficial properties on colon, breast, and prostate cancer⁶⁹.

Pancreas

The same molecular mechanism previously described to explain a possible link between GLP-1

RAs and acute pancreatitis could theoretically lead to the development of pancreatic cancer. In a study carried out by Elashoff, et al. where the AERS was analyzed, it was reported that pancreatic cancer was 2.9-fold higher in patients using exenatide than in patients exposed to other therapies⁷².

Eleven studies on pancreatic cancer associated with exenatide reported to the Drug Commission of the German Medical Association were recently analyzed. Exposure to exenatide was relatively short (2-33 months). Thus, there is considerable doubt that the cases were related to the medication. The time between tumor induction, tumor development, and metastasis/clinical diagnosis was ~ 10 years⁷³.

A study carried out where pancreatic tissue from organ donors with T2DM taking sitagliptin (n = 7), exenatide (n = 1) or other medications (n = 12) and from a non-diabetic subject group (n = 14) found that 40% of patients treated with incretin-mimetic drugs had an increased pancreatic mass. Moreover, patients receiving incretin-mimetic drugs had a-cell hyperplasia and glucagon-expressing microadenomas (3/8) and one had a neuroendocrine tumor⁷⁴. This study is insufficient to draw conclusions as only one of the studied patients was receiving a GLP-1 RA⁷⁵.

A meta-analysis of 25 studies showed that the use of exenatide (OR 0.86; 95% CI: 0.29-2.60) and liraglutide (OR 1.35; 95% CI: 0.70-2.59) did not significantly increase the risk of pancreatic cancer, independently of the baseline comparison⁷⁶.

A study carried out using human pancreatic cancer cell lines showed that these express the GLP-1 receptor, but the findings have been inconsistent as to whether GLP-1 RAs may have pro-oncogenic characteristics⁷⁷. Another group of investigators was unable to detect GLP-1 receptors in 21 human pancreatic adenocarcinomas, which suggests that GLP-1 receptor expression may be restricted to cell lines⁷⁸.

The ELIXA study did not find any differences in regard to the presence of pancreatic neoplasms in 6,068 patients with T2DM who were followed for a median of 25 months when compared with

placebo⁵⁵. Similar findings are expected with the other GLP-1 RA long-term studies.

Thyroid

Concerns have also been expressed regarding a possible link between GLP-1 RAs and medullary thyroid cancer⁷², which are based principally on rodent studies.

Liraglutide, exenatide, lixisenatide, and native GLP-1 have shown a potential to activate thyroid C-cell GLP-1 receptors and stimulate calcitonin release by the increase of calcitonin gene expression⁷⁸, which seems to be species-specific. In rodents, GLP-1 receptor density in thyroid C-cells is from 20- to 45-fold higher than that reported for humans and monkeys^{78,79}.

Liraglutide and exenatide have been associated with the development of thyroid C-cell tumors in rodents after lifetime exposure at supra-therapeutic doses⁷⁸. During a 13-week continuous exposure to GLP-1 RAs, an increase in plasma calcitonin and C-cell hyperplasia was found in wild-type mice but not in GLP-1 receptor knockout mice⁷⁹. Studies carried out with monkeys did not find an increase in calcitonin release or any effect on C-cell fraction in the thyroid gland after an 87-week intervention with liraglutide with a 60-fold higher dose than the highest dose recommended in humans⁷⁸.

Despite the hypothesis that only rodents are sensitive to developing thyroid cancer after exposure to GLP-1 RAs, one of the end-points of recent studies with GLP-1 RAs on humans is the increase in calcitonin release and other possible markers of thyroid carcinoma⁸⁰.

Some studies have recently challenged the hypothesis that normal human thyroid tissue does not express the GLP-1 receptor. In one study it was found that GLP-1 receptors are expressed in thyroid tissue of controls (5/15 cases) and in the thyroid of patients with C-cell hyperplasia (9/9 cases), papillary carcinoma (3/15 cases), and medullary carcinoma (11/12)⁸¹.

Data obtained from different prospective clinical studies showed no increased calcitonin levels under

therapy with GLP-1 RAs in patients with T2DM^{78,82}. In the AERS database the incidence rate of thyroid cancer in patients treated with exenatide was clearly higher compared with other control drugs⁷².

In clinical trials only five cases of thyroid neoplasm were reported with exenatide twice daily and only three adverse thyroid-related events were reported with once-weekly exenatide^{37,40}.

In liraglutide-exposed patients, 12 serious adverse thyroid events were reported, which corresponds to 0.2% of treatment-exposed patients. Also, in all patients who participated in the liraglutide clinical trial programs, serum calcitonin concentrations were monitored as a biomarker for C-cell proliferation, and no increases were observed throughout the trials³⁹.

Treatment with lixisenatide during the clinical development program did not produce trends in the incidence of thyroid neoplasms in comparison to placebo or other comparison groups. Calcitonin levels also remained stable over time³⁸.

Across the phase III head-to-head studies among GLP-1 RAs, mean calcitonin levels were largely unchanged, and only one case of treatment-emergent thyroid cancer was observed (a papillary thyroid carcinoma in a patient with liraglutide in AWARD-6)⁸³. Cases of medullary thyroid carcinoma have been reported in patients treated with liraglutide during the post-marketing period, although data are insufficient to establish or exclude a causal relationship⁸⁴.

Although evidence indicates that there is no relationship between GLP-1 RAs and thyroid cancer or hyperplasia, the longer-acting GLP-1 RAs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple neoplasia syndrome²⁹.

Other tissues

Unlike the effect of GLP-1 RAs on pancreatic and thyroid cancers, GLP-1 receptor activation by GLP-1 RAs is believed to inhibit tumor growth in two common cancers: colon and breast⁶⁸.

In a study carried out using CT26 murine colon cancer cell line, which expresses a GLP-1 receptor,

exenatide inhibited proliferation and induced cell apoptosis and also reduced colony formation and enhanced irinotecan-induced apoptosis⁸⁵. This was confirmed in an *in vivo* study where exenatide induced apoptosis of CT26 cells implanted into the flanks of mice⁸⁶.

Some data have also been published about the relationship between GLP-1 RAs and breast cancer. *In vitro* exposure to exenatide significantly reduced the number of colonies formed by MCF-7 (estrogen-receptor-positive) and MDA-MB-231 (estrogen-receptor-negative) cells, whereas noncancerous HB2 cells were not affected⁸⁷. A possible mechanism of action of exenatide is that it induces p38 activation, which is related with growth inhibition or apoptosis⁸⁸. However, the classic GLP-1 receptor has not been identified in breast cancer cells. Actions must thus be mediated through a not-yet identified alternative receptor.

TOLERABILITY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS

The GLP-1 RAs are generally well tolerated, with the most common side effects being gastrointestinal with mild and transient nausea^{49,89}. The incidence of nausea seems to be higher with the short-acting agents, possibly because of fluctuations in plasma GLP-1 concentrations^{90,91}. Nausea incidence has been observed to decrease over time with continued dosing for both short- and long-acting GLP-1 RAs^{92,93}.

Other common adverse gastrointestinal effects reported with the use of GLP-1 RAs are diarrhea and vomiting, but are less frequent with longer-acting formulations^{84,94,95}. Over time, these are often self-limiting for some patients. Less than 5% discontinued GLP-1 RAs in clinical trials due to gastrointestinal effects, but higher rates of discontinuation (5-10%) are seen in clinical practice. These adverse effects could be reduced by a slow dose-titration^{96,97}.

In clinical trials, patients treated with once-weekly exenatide presented less nausea (25 vs. 35%) and

vomiting (11 vs. 19%) than patients treated with once-daily exenatide⁹⁸. Phase III studies comparing once-daily liraglutide vs. once-weekly exenatide also found a lower incidence of nausea (9 vs. 20%) and vomiting (4 vs. 11%)⁹². In relation to short-acting GLP-1 RAs, phase III studies show a lower incidence of nausea and vomiting in patients treated with lixisenatide than with once-daily exenatide (25 vs. 35%, respectively)⁹⁷.

There are different mechanisms by which GLP-1 RAs could cause gastrointestinal symptoms. One of the principal mechanisms is that this medication slows gastric emptying, which decreases the velocity of the passage of nutrients through the gastrointestinal tract, inducing satiety and possibly nausea⁹⁹. It is also possible that these effects could be mediated through the central nervous system. A study conducted in rats described that central administration of a GLP-1 induced some taste displeasures⁹⁸.

CONCLUSIONS

The decision to use any medication must always be based on efficacy, safety, and patient factors. Despite current evidence that the use of GLP-1 RAs is safe, long-term pharmaceutical studies will continue to evaluate cardiovascular and other adverse outcomes with their use. Evidence is still lacking due to the relatively short time that these medications have been on the market.

For this reason, all types of analyses performed during the post-marketing period, such as observational studies, reviews, and meta-analyses, are valuable for pharmacovigilance activities and to detect safety issues in a timely manner. Most safety-related drug problems emerge after market approval.

Despite the fact that many of the doubts related to the safety of GLP-1 RAs are being resolved and much of this information indicates that their use is safe, it is mandatory to continue to carry out these studies to develop a complete safety profile of GLP-1 RAs and to promptly detect any potential, yet unknown, risks.

REFERENCES

1. Lindamood CA, Taylor JR. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists. *Clin Ther*. 2015;37:483-93.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*. 2012;55:1577-96.
3. Garber AJ, Abrahamson MJ, Barzilay JJ, et al. AACE comprehensive diabetes management algorithm 2013. *Endocr Pract*. 2013;19:327-36.
4. Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. *Int J Clin Pharm*. 2013;35:159-72.
5. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and β -cell function in type 2 diabetes: a parallel-group study. *Lancet*. 2002;359:824-30.
6. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. *Am J Physiol Endocrinol Metab*. 2004;287:E1209-15.
7. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. *J Nucl Med*. 2007;48:736-43.
8. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. *Diabetes Metab Res Rev*. 2011;27:528-42.
9. Cryer PE. Hypoglycaemia: the limiting factor in glycemic management of type I and type II diabetes. *Diabetologia*. 2002;45:937-48.
10. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. *J Clin Endocrinol Metab*. 2002;87:1239-46.
11. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. *Diabetes*. 2004;53:2397-403.
12. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther*. 2008;30:1448-60.
13. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*. 2009;373:39-47.
14. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care*. 2009;32:84-90.
15. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycemic control and weight in overweight metformin-treated patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2006;8:419-28.
16. Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. *Diabetes Med*. 2010;27:1024-32.
17. de Heer J, Holst JJ. Sulfonyleurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. *Diabetes*. 2007;56:438-43.
18. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients in type 2 diabetes (DURATION-3): an open-label randomized trial. *Lancet*. 2010;26:2234-43.
19. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. *Br J Clin Pharmacol*. 2007;64:317-27.
20. Byetta (exenatide)-renal failure 2009. Available at: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.html> [Accessed 03 Feb 2016].
21. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment. *Diabetologia*. 2007;50(Suppl. 1):S352.
22. Flint A, Nazzari K, Jagielski P. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide. *Diabetes*. 2007;56(Suppl. 1):A145.

23. Victoza (Summary of Product Characteristics). Novo Nordisk A/S: Bagsvaerd, Denmark. 2009. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001026/human_med_001137.jsp&url=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124. [Accessed 05 Feb 2016].
24. Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcomes results (LEADER) trial. *Am Heart J*. 2013;166:823-30.
25. Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. *Endocrine*. 2014;46:406-19.
26. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. *Cardiovasc Diabetol*. 2010;3:32.
27. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. *J Am Soc Nephrol*. 2007;18:1227-38.
28. Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? *Nat Rev Nephrol*. 2014;10:88-103.
29. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. *Drugs Context*. 2015;4:212283.
30. Rossman HS. Neutralizing antibodies to multiple sclerosis treatments. *J Manag Care Pharm*. 2004;10:S12-19.
31. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin(9-39) an antagonist of the receptor. *Diabetes*. 1993;42:1678-82.
32. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. *J Med Chem*. 2000;43:1664-9.
33. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. *Lancet*. 2008;372:1240-50.
34. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analog, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabet Med*. 2009;26:268-78.
35. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). *Diabetes Care*. 2009;32:1224-30.
36. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy, and cross-reactivity with long-term treatment. *Diabetes Obes Metab*. 2012;14:546-54.
37. Exenatide SPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000698/WC500051845.pdf [Accessed 04 Feb 2016].
38. Lixisenatide SPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC5000140401.pdf [Accessed 04 Feb 2016].
39. Liraglutide SPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf [Accessed 04 Feb 2016].
40. Exenatide once weekly SPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC5000108241.pdf. [Accessed 04 Feb 2016].
41. Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists treatment: a meta-analysis of randomized controlled trials. *Endocrine*. 2015;48:107-15.
42. Filipatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. *Rev Diabet Stud*. 2014;11:202-30.
43. Bunck MC, Eliasson B, Corner A, et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. *Diabetes Obes Metab*. 2011;13:374-7.
44. Food and Drug Administration. (2008). Guidance for Industry: Diabetes mellitus: Evaluating cardiovascular risk in new diabetic therapies to treat type 2 diabetes. US Department of Health and Human Services.
45. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2014;16:38-47.
46. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. *J Hypertens*. 2003;21:1125-35.
47. Davies MJ, Kela R, Khunti K. Liraglutide—overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. *Diabetes Obes Metab*. 2011;13:207-20.
48. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. *Diabetes Care*. 2012;35:252-8.
49. Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. *Expert Opin Drug Saf*. 2015;14:207-18.
50. Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. *Diab Vasc Dis Res*. 2012;9:95-108.
51. US National Institutes of Health. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus.
52. Haluzik M, Trachta P, Mráz M. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide.] *Vnitř Lek*. 2015;61:635-40.
53. Scheen AJ. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. *Expert Rev Clin Pharmacol*. 2016;9:385-99.
54. US National Institutes of Health. Effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in subjects with type 2 diabetes mellitus.
55. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med*. 2015;373:2247-57.
56. Noel R, Braun D, Patterson R, Bloomgren G. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. In: 24th International Conference of Pharmacoepidemiology and Therapeutic Risk Management; 2008; Copenhagen, Denmark. International Society of Pharmacoepidemiology; 2008. [Abstract].
57. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. *Lancet*. 2008;371:143-52.
58. Blomgren KB, Sundstrom A, Steineck G, Wiholm BE. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. *Diabetes Care*. 2002;25:298-302.
59. US Food and Drug Administration-Center for Drug Evaluation and Research. Exenatide (marked as BYETTA): acute pancreatitis; 2008. Available at: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150839.htm> [Accessed 7 Feb 2016].
60. US Food and Drug Administration-Center for Drug Evaluation and Research. Information for healthcare professionals: exenatide (marked as BYETTA)—8/2008 update. 2008. Available at: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm> [07 Feb 2016].
61. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomized and non-randomized studies. *BMJ*. 2014;348:1-19.
62. Weaver J, Willy M, Avigan M. Informatic tools and approaches in post-marketing pharmacovigilance used by FDA. *AAPS J*. 2008;10:35-41.
63. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. *Endocrinology*. 2014;155:1280-90.
64. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. *Diabetes*. 2009;58:2148-61.
65. Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. *Diabetes*. 2012;61:1243-9.
66. Devaraj S, Maitra A. Pancreatic safety of newer incretin-based therapies: are the "tides" finally turning? *Diabetes*. 2014;63:2219-21.
67. Drucker DJ, Mojsos S, Habener JF. Cell-specific post-translational processing of preproglucagon expressed from metallothionein-glucagon fusion gene. *J Biol Chem*. 1986;261:9637-43.
68. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. *Diabetes*. 2000;49:741-8.
69. Vangoitsenhoven R, Mathieu C, Van der Schueren B. GLP-1 and cancer: friend or foe? *Endocr Relat Cancer*. 2012;19:F77-88.
70. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med*. 2011;364:829-41.

71. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. *Diabetes Care*. 2010;33:1674-85.
72. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-q based therapies. *Gastroenterology*. 2011;141:150-6.
73. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature*. 2010;467:1114-17.
74. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. *Diabetes*. 2013;62:2595-605.
75. Bonner-Weir S, In't Veld PA, Weir GC. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. *Diabetes Obes Metab*. 2014;16:661-6.
76. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. *Diabetes Res Clin Pract*. 2012;98:271-84.
77. Koehler JA, Drucker DJ. Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. *Diabetes*. 2006;55:1369-79.
78. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. *Endocrinology*. 2010;151:1473-86.
79. Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. *Endocrinology*. 2012;153:1538-47.
80. Waser B, Beetschen K, Pellagata NS, Reubi JC. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. *Neuroendocrinology*. 2011;94:201-301.
81. Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW. Glucagon like peptide-1 receptor expression in the human thyroid gland. *J Clin Endocrinol Metab*. 2012;97:121-31.
82. Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. *J Clin Endocrinol Metab*. 2011;96:853-60.
83. Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. *Diabetes Obes Metab*. 2016;18:317-32.
84. Shaefer CF Jr, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. *Postgrad Med*. 2015;127:818-26.
85. Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ. Glucagon-like peptide-2 does not modify the growth of survival of murine or human intestinal tumor cells. *Cancer Res*. 2008;68:7897-904.
86. Koehler JA, Kain T, Drucker DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. *Endocrinology*. 2011;152:3362-72.
87. Ligumsky H, Wolf I, Israeli S, et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. *Breast Cancer Res Treat*. 2012;132:449-61.
88. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. *Science*. 1995;270:1326-31.
89. Samson SL, Garber A. GLP-1R agonist therapy for diabetes: benefits and potential risks. *Curr Opin Endocrinol Diabetes Obesity*. 2013;20:87-97.
90. Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. *Pharmacotherapy*. 2014;34:1174-86.
91. Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. *Eur J Intern Med*. 2014;25:407-14.
92. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized, open-label study. *Lancet*. 2013;381:117-24.
93. Macconell L, Gurney K, Malloy J, Zhou M, Kolterman O. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. *Diabetes Metab Syndr Obes*. 2015;8:241-53.
94. Vilsboll T, Christensen M, Junker A, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: a systematic review and meta-analysis of randomized controlled trials. *BMJ*. 2012;344:d7771.
95. AACE 2015 guidelines type 2 diabetes. Available at: <http://www.aace.com/files/dm-guidelines-ccp.pdf>. (Accessed 11 Feb 2016).
96. Rosenstock J, Balas B, Charbonnel B, et al. The effect of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes. The T-Emerge 2 trial. *Diabetes Care*. 2013;36:498-504.
97. Rosenstock J, Raccach D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care*. 2013;36:2945-51.
98. Thiele TE, Van Disk G, Campfield LA, et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversion in rats. *Am J Physiol*. 1997;272:R726-30.
99. Feinle C, Christen M, Grundy D, et al. Effects of duodenal fat, protein or mixed-nutrient infusion on epigastric sensations during sustained gastric distention in healthy humans. *Neurogastroenterol Motil*. 2001;14:205-13.